T. Kokten, F. Hansmannel, H. Melhem, and L. Peyrin-biroulet, Physiopathologie des maladies inflammatoires chroniques de l'intestin (MICI). HEGEL, vol.6, pp.119-148, 2016.

J. F. Swart, . Roock-s-de, and B. J. Prakken, Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype, European Journal of Immunology, vol.46, pp.2068-77, 2016.

M. Noack and M. Kolopp-sarda, Cytokines et inflammation : physiologie, physiopathologie et utilisation thérapeutique. Revue Francophone des Laboratoires, vol.499, pp.28-37, 2018.

S. Auvin, F. Molinié, C. Gower-rousseau, F. Brazier, M. V. Grandbastien et al.,

, Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999), J Pediatr Gastroenterol Nutr, vol.41, pp.49-55, 2005.

A. Peneau, G. Savoye, D. Turck, L. Dauchet, M. Fumery et al., Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study, Am J Gastroenterol, vol.108, pp.1647-53, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01704624

D. Corica and C. Romano, Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review, J Clin Gastroenterol, vol.51, pp.100-110, 2017.

S. Thierry, B. Fautrel, I. Lemelle, and F. Guillemin, Prévalence et incidence de l'arthrite juvénile idiopathique : revue de la littérature, Revue du rhumatisme, vol.81, pp.123-130, 2014.

C. Deslandre, Arthrite juvénile idiopathique : définition et classification. Archives de pédiatrie, vol.23, pp.437-478, 2015.

Y. Guex-crosier, J. Vaudaux, and M. Hofer, Prise en charge d'une uvéite pédiatrique, Paediatrica, vol.26, p.5, 2015.

M. M. Tollefson, C. S. Crowson, M. T. Mcevoy, and H. M. Kremers, Incidence of psoriasis in children: a population-based study, J Am Acad Dermatol, p.62, 2010.

G. Swanbeck, A. Inerot, T. Martinsson, J. Wahlström, C. Enerbäck et al., Age at onset and different types of psoriasis, Br J Dermatol, vol.133, pp.768-73, 1995.

F. Nuti, F. Viola, F. Civitelli, C. Alessandri, M. Aloi et al., Biological therapy in a pediatric Crohn disease population at a referral center, J Pediatr Gastroenterol Nutr, 2014.

S. Dogra and R. Mahajan, Biologics in pediatric psoriasis -efficacy and safety, Expert Opin Drug Saf, vol.17, pp.9-16, 2018.

S. M. Al-mayouf, A. Alenazi, and H. Aljasser, Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety, Int J Rheum Dis, vol.19, pp.600-605, 2016.

E. Szymanska, M. Dadalski, G. Oracz, and J. Kierkus, Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease, Prz Gastroenterol, vol.10, pp.164-172, 2015.

P. S. Dulai, K. D. Thompson, H. B. Blunt, M. C. Dubinsky, and C. A. Siegel, Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review, Clin Gastroenterol Hepatol, vol.12, pp.1443-51, 2014.

H. I. Brunner, N. Ruperto, Z. Zuber, C. Keane, O. Harari et al., Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial, Ann Rheum Dis, vol.74, pp.1110-1117, 2015.

S. H. Machado and R. M. Xavier, Safety of tocilizumab in the treatment of juvenile idiopathic arthritis, Expert Opin Drug Saf, vol.16, pp.493-500, 2017.

T. Kullenberg, M. Löfqvist, M. Leinonen, R. Goldbach-mansky, and H. Olivecrona, Longterm safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes, Rheumatology (Oxford), vol.55, pp.1499-506, 2016.

S. Yokota, T. Imagawa, R. Nishikomori, H. Takada, K. Abrams et al., Longterm safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients, Clinical and Experimental Rheumatology, vol.8, pp.19-26, 2017.

E. Fréling, C. Baumann, J. Cuny, M. Bigard, J. Schmutz et al., Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience, Am J Gastroenterol, vol.110, pp.1186-96, 2015.

S. Segaert and C. Hermans, Clinical Signs, Pathophysiology and Management of

, Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents, Am J Clin Dermatol, vol.18, pp.771-87, 2017.

T. Mälkönen, A. Wikström, K. Heiskanen, L. Merras-salmio, H. Mustonen et al., Skin reactions during anti-TNF? therapy for pediatric inflammatory bowel disease: a 2-year prospective study, Inflamm Bowel Dis, vol.20, p.77, 2014.

J. Klotsche, M. Niewerth, J. Haas, H. Huppertz, A. Zink et al., Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA), Ann Rheum Dis, vol.75, pp.855-61, 2016.

D. Windschall and G. Horneff, Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis, Clin Rheumatol, vol.35, pp.2925-2956, 2016.

O. Ledder, A. Assa, A. Levine, J. C. Escher, L. De-ridder et al.,

, Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN, J Crohns Colitis, vol.11, pp.1230-1237, 2017.

A. Gül, H. Ozdogan, B. Erer, S. Ugurlu, O. Kasapcopur et al., Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever, Arthritis Res Ther, vol.17, 2015.

H. I. Brunner, N. Ruperto, N. Tzaribachev, G. Horneff, V. G. Chasnyk et al.,

, Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial, Ann Rheum Dis, vol.77, pp.21-30, 2018.

M. Ferrante, S. Vermeire, and P. J. Rutgeerts, Drug safety evaluation of certolizumab pegol, Expert Opin Drug Saf, vol.13, pp.255-66, 2014.

M. Aloi, M. Bramuzzo, S. Arrigo, C. Romano, D. 'arcangelo et al., Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry, J Pediatr Gastroenterol Nutr, vol.66, pp.920-925, 2018.

E. Feist, P. Quartier, B. Fautrel, R. Schneider, P. Sfriso et al., Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups, Clinical and Experimental Rheumatology, vol.36, pp.668-675, 2018.

M. Tarkiainen, P. Tynjälä, P. Vähäsalo, and P. Lahdenne, Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting, Rheumatology, vol.54, pp.1170-1176, 2015.

S. J. Hayat and S. S. Uppal, Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus, Mod Rheumatol, vol.17, pp.174-181, 2007.

M. Aringer, W. B. Graninger, G. Steiner, and J. S. Smolen, Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study, Arthritis Rheum, vol.50, pp.3161-3170, 2004.

D. Micheloud, L. Nuño, M. Rodríguez-mahou, S. Sánchez-ramón, M. C. Ortega et al., Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy, Lupus, vol.15, pp.881-886, 2006.

E. S. Kim, K. P. Garnock-jones, and S. J. Keam, Adalimumab: A Review in Hidradenitis Suppurativa, Am J Clin Dermatol, vol.17, pp.545-52, 2016.

C. Tillack, L. M. Ehmann, M. Friedrich, R. P. Laubender, P. Papay et al.,

, Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-?-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment, Gut, vol.63, pp.567-77, 2014.

A. N. Collamer, K. T. Guerrero, J. S. Henning, and D. F. Battafarano, Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action, Arthritis Care & Research, vol.59, pp.996-1001, 2008.

I. Cleynen, W. Van-moerkercke, T. Billiet, P. Vandecandelaere, V. Casteele et al.,

C. Breynaert, Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study, Ann Intern Med, vol.164, pp.10-22, 2016.

H. Fidder, F. Schnitzler, M. Ferrante, M. Noman, K. Katsanos et al., Longterm safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study, Gut, vol.58, pp.501-509, 2009.

M. W?odarczyk, A. Sobolewska, B. Wójcik, K. Loga, J. Fichna et al.,

M. , Correlations between skin lesions induced by anti-tumor necrosis factor-? and selected cytokines in Crohn's disease patients, World J Gastroenterol, vol.20, pp.7019-7045, 2014.

M. Flendrie, W. H. Vissers, M. C. Creemers, E. M. De-jong, P. C. Van-de-kerkhof et al., Dermatological conditions during TNF-?-blocking therapy in patients with rheumatoid arthritis: a prospective study, Arthritis Res Ther, vol.7, pp.666-76, 2005.

G. Hiremath, L. Duffy, and I. Leibowitz, Infliximab-induced psoriasis in children with inflammatory bowel disease, J Pediatr Gastroenterol Nutr, vol.52, pp.230-232, 2011.

M. E. Sherlock, T. Walters, M. M. Tabbers, K. Frost, M. Zachos et al., Infliximabinduced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms, J Pediatr Gastroenterol Nutr, vol.56, pp.512-520, 2013.

O. Courbette, C. Aupiais, J. Viala, J. Hugot, B. Louveau et al., , p.79

, Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease, J Pediatr Gastroenterol Nutr, vol.69, pp.189-93, 2019.

S. Park, P. Hwang, Y. Kim, H. Park, and J. , Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature, Ann Dermatol, vol.29, pp.74-82, 2017.

J. Sota, A. Vitale, A. Insalaco, P. Sfriso, G. Lopalco et al., Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study, Clin Rheumatol, vol.37, pp.233-2240, 2018.

I. Pontikaki, E. Shahi, L. A. Frasin, R. Gianotti, C. Gelmetti et al., Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis, Clin Rev Allergy Immunol, vol.42, pp.131-135, 2012.

D. J. Lovell, N. Ruperto, R. Mouy, E. Paz, N. Rubio-pérez et al., Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years, Arthritis Rheumatol, vol.67, pp.2759-70, 2015.

J. Seneschal, B. Milpied, B. Vergier, S. Lepreux, T. Schaeverbeke et al., Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments, Br J Dermatol, vol.161, pp.1081-1089, 2009.

. Gannes-gc-de, M. Ghoreishi, J. Pope, A. Russell, D. Bell et al., Psoriasis and Pustular Dermatitis Triggered by TNF-? Inhibitors in Patients With Rheumatologic Conditions, Arch Dermatol, vol.143, pp.223-254, 2007.

A. K. Palucka, J. Blanck, L. Bennett, V. Pascual, and J. Banchereau, Cross-regulation of TNF and IFN-? in autoimmune diseases, Proc Natl Acad Sci U S A, vol.102, pp.3372-3379, 2005.

G. Piskin, R. Sylva-steenland, J. D. Bos, and M. Teunissen, In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin, The Journal of Immunology, vol.176, pp.1908-1923, 2006.

G. Horneff, Biologic-associated infections in pediatric rheumatology, Curr Rheumatol Rep, vol.17, p.66, 2015.

M. Tauber, S. Buche, P. Reygagne, J. Berthelot, F. Aubin et al.,

, Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study, J Am Acad Dermatol, vol.70, pp.1146-1155, 2014.

F. Osório, F. Magro, C. Lisboa, S. Lopes, G. Macedo et al., Anti-TNFalpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature, Dermatology (Basel), vol.225, p.80, 2012.

G. Cullen, D. Kroshinsky, A. S. Cheifetz, and J. R. Korzenik, Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature, Alimentary Pharmacology & Therapeutics, vol.34, pp.1318-1345, 2011.

M. J. Harrison, W. G. Dixon, K. D. Watson, Y. King, R. Groves et al., Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor ? therapy: results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis. 2 avr, vol.68, pp.209-224, 2008.

L. A. George, A. Gadani, R. K. Cross, G. Jambaulikar, and L. J. Ghazi, Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease, Dig Dis Sci, vol.60, pp.3424-3454, 2015.

H. Lee, I. Song, M. Friedrich, A. Gauliard, J. Detert et al., Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factoralpha antagonists, Br J Dermatol, vol.156, pp.486-91, 2007.

J. Listing, A. Strangfeld, S. Kary, R. Rau, . Hinueber-u-von et al., Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis & Rheumatism, vol.52, pp.3403-3415, 2005.

D. M. Klufas, J. M. Wald, and B. E. Strober, Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series, Pediatr Dermatol, vol.33, pp.142-151, 2016.

D. Wendling, G. Streit, E. Toussirot, and C. Prati, Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease, Joint Bone Spine, vol.75, p.81, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00465182